Pancreatic Cancer Therapy
Study findings on pancreatic cancer therapy are outlined in reports from Saga University, Department of Surgery
Published in Cancer Weekly, March 23rd, 2010
Investigators publish new data in the report 'Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.' According to recent research from Saga, Japan, "Gemcitabine (Gem) is a dFdC analogue with activity against several solid tumors. Gem is intracellularly phosphorylated by dCK, leading to the production of the metabolite dFdCDP. dFdCDP exhibits the cytotoxic effect by inactivating ribonucleotide reductase larger subunit 1 (RRM1), which is a rate limiting enzyme for de novo DNA synthesis."
"To date, RRM1 expression is believed to determine sensitivity to Gem in pancreatic and non-small cell lung...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-03-23)
More Articles from Cancer Weekly
- American Cancer Society
Improvements needed in genomic test result discussions - American Cancer Society
Study finds cancer mortality has declined since initiation of 'war on cancer' - Columbia University Medical Center
Acupuncture may relieve joint pain caused by some breast cancer treatments - EQ Biosciences, Inc.
Supplement blocks the initiation of breast cell mutations by estrogens - Journal of the National Cancer Institute
High weight associated with risk of colorectal tumors without microsatellite instability - University of Leicester
MRC scientists announce advance in understanding body's natural defenses - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
